Latest News from "The Pink Sheet" DAILY - Novartis' Sandoz Unit Makes Respiratory Push

Pharmerging Markets Expected To Keep Sales Growth "Strong" Through 2014, IMS Says

IMS forecasts a 5 percent to 8 percent growth of global pharmaceutical sales annually through 2014. read_more_>

 

CMS Administrator-Nominee Berwick Is In Position To Redefine CMS' Policy Role

Harvard management professor and pediatrician Donald Berwick is tapped for the top CMS post as health reform moves into the implementation phase. read_more_>

 

Lilly Slashes Revenue Forecasts For 2010 And 2011 Due To Health Care Reform

The drug maker blames changes to various government programs for revenue that will drop by hundreds of millions of dollars. read_more_>

 

Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says

Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals. read_more_>

 

Novartis' Sandoz Unit Makes Respiratory Push With Acquisition Of Oriel

Buyout of the private U.S. pharma company gives Sandoz a portfolio of generic drug candidates and technologies in asthma and COPD. read_more_>

 

Lundbeck Defends Its Escitalopram Patent In Denmark, But Not In Spain

Lundbeck's top-selling product, Cipralex, is responsible for more than half its sales, but faces generic competition in Spain. read_more_>

 

National Healthcare Quality Report Spotlights High Hospital Infection Rates

An estimated 1.7 million health-care-associated infections, or HAIs, occur each year in hospitals, and nearly 100,000 of those infections lead to death. read_more_>

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here